A Phase II, Open Study of the Clinical Activity, Safety and Tolerability of Lapatinib in Combination with Bevacizumab in Subjects with Advanced or Metastatic ErbB-2-Overexpressing Breast Cancer

-
Investigator: Hope Rugo, MD
Sponsor: GlaxoSmithKline

Location(s): United States

Description

This study will examine the efficacy and safety of lapatinib and bevacizumab in patients with ErbB2-overexpressing breast cancer.